Introduction and Objectives: In light of the expanded marketing authorization for the 13-valent pneumococcal conjugate vaccine (PCV13): 1) To study the incidence and trends of invasive pneumococcal infections in adults (excluding meningitis) according to risk factors (RFs), in conjunction with microbiological data 2) To assess the impact of PCV13. The pilot study aimed to test the feasibility of data collection. Materials and methods: a prospective descriptive cohort study involving the regional pneumococcal surveillance networks (ORP), the CNRP, the SPILF, and the InVS. Microbiological and clinical data are collected by a microbiologist-clinician team. Strains are serotyped at the CNRP. Twenty institutions participated in the pilot phase, which began on October 18, 2012. Results: As of December 9, 2013, 135 cases had been documented (14 cases not documented). The mean age was 70 years, the female-to-male ratio was 1.1; 75% of cases had one risk factor, 54% had two risk factors, and 28% had immunosuppression; 60% had a long-term illness. Only 3% were vaccinated against pneumococcus. The site of infection was pneumonia (73%), pleuropneumonia (15%), another site (5%), and unknown (8%); 33% of cases were admitted to the ICU, 20% were ventilated, and 14% died (9% if 0 FR vs. 15% if 1 FR); the mean length of stay was 19 ± 23 days. 94% of pneumococci were susceptible to amoxicillin, 70% to cefotaxime, and 76% to erythromycin. Three serotypes predominated: 3, 7F, and 19A. The 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine covered 51% and 82% of cases, respectively. Conclusion: The quality of data collection, the involvement of clinician-microbiologist pairs, and the initial results support the expansion of the network. The goal is to include 520 cases annually to assess the impact of PCV13 vaccination based on risk factors, severity, and serotypes. (R.A.)